Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.

ABSTRACT

We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was TP1 25% (±6%) versus 49% (±7%; p = .0009); TP2 21% (±8%) versus 47% (±7%; p < .0001); and TP3 22% (±14%) versus 51% (±6%; p = .0178). For KMT2A-germline patients, 3-year EFS was TP1 88% (±12%) versus 87% (±5%; p = .73); TP2 100% versus 88% (±5%; p = .24); and TP3 100% versus 87% (±5%; p = .53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.